

INFORMATION IN RELATION TO THE COMPANY FOR REFERENCE

Legal name

Chinese name:	廣州藥業股份有限公司
Chinese abbreviation:	廣州藥業
English name:	Guangzhou Pharmaceutical Company Limited
English abbreviation:	GPC

Legal representative:


Cai Zhixiang

Company Secretary

Name:	He Shuhua
Address:	45 Sha Mian North Street, Guangzhou City, Guangdong Province, PRC
Telephone:	(8620) 8121 8117
Fax:	(8620) 8187 6408
Company Secretary E-mail:	shuhua_he@sina.com

Registered office addresses:

The PRC registered office address:	45 Sha Mian North Street, Guangzhou City, Guangdong Province, PRC
Post code:	510130
Telephone:	(8620) 8121 8103
Fax:	(8620) 8187 6408
Website:	http://www.gzphar.com
E-mail:	sec@gpc.com.cn
Principal business address in Hong Kong:	Room 2005, 20th Floor, Tower Two, Lippo Center, 89 Queensway, Hong Kong



Newspapers designated by the Company to disclose information:

Shanghai Securities Daily
China Securities
Hong Kong Economic Daily
Hong Kong iMail

Internet website publishing annual report designated by:

The China Securities Regulatory Commission
The Stock Exchange of Hong Kong Limited

<http://www.sse.com.cn>
<http://www.hkex.com.hk>

Place where the annual report is available for inspection:

Company Secretary Office
Guangzhou Pharmaceutical Co Ltd
2nd Floor, 45 Sha Mian North Street,
Guangzhou City,
Guangdong Province,
PRC

Place of listing of shares and trading codes:

A shares:
Shanghai Stock Exchange
Stock code: 600332
Stock name: GZ Phar.
H shares:
The Stock Exchange of Hong Kong Limited
Stock code: 0874
Stock name: GZ Phar.

COMPANY STATUS

Background of the Company

Guangzhou Pharmaceutical Company Limited (the “Company”) is a joint stock company with limited liability established in the People’s Republic of China (the “PRC”) on 1 September 1997 pursuant to a re-organization in 1997 of eight Chinese patent medicine manufacturing entities and three pharmaceutical trading entities formerly under the supervision and control of Guangzhou Pharmaceutical Holdings Limited (“GZPHL”). The Company’s H shares were listed on The Stock Exchange of Hong Kong Limited (the “HKSE”) on 30 October 1997. Upon obtaining approval from the Chinese Securities Regulatory Commission (the “CSRC”) on 10 January 2001, the Company issued 78,000,000 Reminbi A shares in China. The Company’s A shares were officially listed on the Shanghai Stock Exchange (the “SSE”) on 6 February 2001.

Scope of business

The Company and its subsidiaries (the “Group”) are principally engaged in (i) the manufacture and sale of Chinese patent medicine (“CPM”) and (ii) the wholesale, retail, import and export of Western and Chinese pharmaceutical products and various medical apparatus.